Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Complete title: SC-2025, Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Research Study Number SC-2025
 
Principal Investigator Todd Cooper
 
Phase I

Research Study Description

This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-2025
 
Contact Advanced Therapeutics Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Leukemia, Myeloid; Leukemia, Lymphoid; Immunoproliferative Disorders; Myeloproliferative Disorders (MPD); Bone Marrow Diseases; Leukemia, Chronic Myelogenous; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials